Table 1.
Antitumor activity of ZnPc-(Lys)5 against an S180 tumor model implanted in Kunming mice.[a]
| PDT Treatment | Body weight [g] | Tumor weight [g] | Inhibition [%] | |
|---|---|---|---|---|
| Day 1 | Day 10 | |||
| Vehicle | 30.4±1.0 | 35.6±2.2 | 2.08±0.14 | – |
| 0.5 mgkg−1 ZnPc-(Lys)5 | 30.2±0.9 | 32.4±1.9 | 0.80±0.10* | 61.4 |
| 1 mgkg−1 ZnPc-(Lys)5 | 30.3±0.8 | 34.1±2.0 | 0.28±0.04* | 86.8 |
| 2 mgkg−1 ZnPc-(Lys)5 | 31.1±0.7 | 32.6±1.9 | 0.32±0.05* | 84.4 |
| 2 mgkg−1 ZnPc-(Lys)5, dark | 29.6±0.9 | 33.2±1.7 | 1.08±0.12* | 47.9 |
| Light, no photosensitizer | 30.6±1.2 | 35.3±1.4 | 1.33±0.21* | 35.9 |
[a]
12 h after injection of the indicated amount of ZnPc-(Lys)5, tumors were illuminated once with laser light (λ 670 nm, 217 mW cm−2) for a total fluence of 65 J cm−2. Data represent the mean ± SEM of n =7 experiments in each case, and were analyzed using a one-way ANOVA and Newman–Keuls test;
*
indicates significant difference (at p <0.01) from vehicle control.